Sou Hu Cai Jing·2025-08-11 12:02Core Viewpoint - Haohai Biological Technology Co., Ltd. is currently trading at 54.9 yuan with a PE ratio of 30.90, which is significantly lower than the industry average of 56.56 [1][2] Company Summary - The main business of Haohai Biological includes the research, production, and sales of medical devices and pharmaceuticals, with key products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1] - As of February 29, 2020, the number of shareholders increased to 7,605, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - In the first quarter of 2025, the company reported a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41% year-on-year, with a gross margin of 69.52% [1] Industry Comparison - The average PE ratio for the medical device industry is 56.56, while the median is 39.76, positioning Haohai Biological at the 59th rank within the industry [1][2]